1Greenberg PAC, Hortobagpy GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer[J]. J Clin Oncol, 1996 ; 14:2197-205.
2Sledge GW, Neuberg D, Bermardo P, et al. Phase 111 trial or doxorubicin, paclitaxel, and the combination or doxorubicin and paclitaxel as front-line chemotherapy for meta- static breast cancer: an intergroup trial( E1193 ) [J]. J Clin Oncol,2003 ;21 (4) : 588-92.
3Citron ML, Berry DA, Cirrincione C, et al. Randomized trim of dose-dense versus conventionally scheduled and sequential versus concurrent combi- nation chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 [ J ]. J C lin Onco1,2003 ;21 (8) :1431-9.
4Razis ED. Gpaclitaxel: epimbicin in metastatic breast cancer a review [J].Ann Oncol,2001 ;12(5):593-S.
